SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    DeVita VT Jr., Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980; 92: 587595.
  • 2
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36: 252259.
  • 3
    Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 14781484.
  • 4
    Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996; 14: 14211430.
  • 5
    Hoppe RT. Hodgkin's disease—the role of radiation therapy in advanced disease. Ann Oncol. 1996; 7 (Suppl 4): 99103.
  • 6
    Mauch P. What is the role for adjuvant radiation therapy in advanced Hodgkin's disease? J Clin Oncol. 1998; 16: 815817.
  • 7
    Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998; 16: 818829.
  • 8
    Andrieu JM, Yilmaz U, Colonna P. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol. 1999; 17: 730734.
  • 9
    Andrieu JM, Weh HJ, Teillet F, Jacquillat C, Boiron M. Localisation pulmonaire de la maladie de Hodgkin. Aspects initiaux et évolution. Nouv Presse Med. 1978; 7: 37373741.
  • 10
    Andrieu JM, Cramer P, Auclerc G, Teillet F. Siège des rechutes dans la maladie de Hodgkin avec atteinte médullaire traitée par polychimiothérapie. Bull Cancer. 1978; 65: 363364.
  • 11
    Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT Jr. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978; 42 (Suppl 2): 10011007.
  • 12
    Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991; 9: 21932201.
  • 13
    Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994; 120: 903912.
  • 14
    Ifrah N, Hunault M, Jais JP, et al. Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. Leuk Lymphoma. 1996; 21: 7984.
  • 15
    Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol. 1996; 14: 19281935.
  • 16
    Andrieu JM, Jais JP, Colonna P, et al. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Ann Oncol. 1998; 9: 195203.
  • 17
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 18601861.
  • 18
    Kaplan HS. Hodgkin's disease, 2nd edition. Cambridge: Harvard University Press, 1980.
  • 19
    Desablens B, Tourani JM, Casassus P, et al. Traitement des formes localisées de la maladie de Hodgkin par 3 cures de chimiothérapie (ABVD-MP) associées à une radiothérapie focale élargie et lombo-splénique prophylactique. Presse Med. 1989; 18: 19171921.
  • 20
    Sweetenham JW, Taghipour G, Milligan D, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997; 20: 745752.
  • 21
    Tourani JM, Levy R, Colonna P, et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol. 1992; 10: 10861094.
  • 22
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35: 139.
  • 23
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980: 122127.
  • 24
    Specht L. Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer. 1992; 28A: 19821985.
  • 25
    Mendenhall NP, Cantor AB, Barre DM, Lynch JW Jr., Million RR. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol. 1994; 17: 189195.
  • 26
    Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR. Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys. 1980; 6: 809813.
  • 27
    Mauch P, Gorshein D, Cunningham J, Hellman S. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep. 1982; 66: 809817.
  • 28
    Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS. The management of Stage I–II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 1982; 59: 455465.
  • 29
    Mazza P, Lauria F, Sciascia R, et al. Prognostic significance of large mediastinal involvement in Hodgkin's disease. Scand J Hematol. 1983; 31: 315321.
  • 30
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown W, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002; 20: 630637.
  • 31
    Diehl V, Franklin J, Paulus U, et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: final analysis of the German Hodgkin Lymphoma Study Group [abstract 3202]. Blood. 2001; 98: 769a.
  • 32
    Saghachian M, Escoffre-Barbe M, Hunault-Berger M, et al. Very high risk Hodgkin's disease: ABVD chemotherapy (4 cycles) followed by BEAM-conditioned autologous stem cell transplantation and focal radiotherapy (RT) versus intensive chemotherapy (3 cycles) followed by involved field RT. Three-year results of the GOELAMS H97-LM multicenter randomized trial [abstract 1128]. Proc Am Soc Clin Oncol. 2001; 20: 283a.
  • 33
    Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998; 16: 1926.
  • 34
    Pavlovsky S, Santarelli MT, Muriel FS, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for Stage III–IV A and B Hodgkin's disease. Ann Oncol. 1992; 3: 533537.
  • 35
    Glick J, Tsiatis A, Rubin P, Bennet J. Improved survival with sequential bleo-MOPP followed by ABVD for advanced Hodgkin's disease (HD): 8-year results [abstract 836]. Blood. 1987; 70 (Suppl 1): 245a.
  • 36
    Glick J, Tsiatis A, Chen M, Rassiga A, Mann R, O'Connel M. Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy for advanced Hodkin's disease: 6-year ECOG results [abstract]. Blood. 1990; 76 (Suppl 1): 350a.
  • 37
    Ferme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial. Blood. 2000; 95: 22462252.